Abstract

Leaflet thrombosis has been suggested as the reason for the reduced leaflet motion in cases of hypoattenuated leaflet thickening of bioprosthetic aortic valves. This work aimed to estimate the risk of leaflet thrombosis in two post-valve-in-valve (ViV) configurations, using five different numerical approaches. Realistic ViV configurations were calculated by modelling the deployments of the latest version of transcatheter aortic valve devices (Medtronic Evolut PRO, Edwards SAPIEN 3) in the surgical Sorin Mitroflow. Computational fluid dynamics simulations of blood flow followed the dry models. Lagrangian and Eulerian measures of near-wall stagnation were implemented by particle and concentration tracking, respectively, to estimate the thrombogenicity and to predict the risk locations. Most of the numerical approaches indicate a higher leaflet thrombosis risk in the Edwards SAPIEN 3 device because of its intra-annular implantation. The Eulerian approaches estimated high-risk locations in agreement with the wall sheer stress (WSS) separation points. On the other hand, the Lagrangian approaches predicted high-risk locations at the proximal regions of the leaflets matching the low WSS magnitude regions of both transcatheter aortic valve implantation models and reported clinical and experimental data. The proposed methods can help optimizing future designs of transcatheter aortic valves with minimal thrombotic risks.

Highlights

  • Transcatheter aortic valve implantation (TAVI) is a minimally invasive intervention whereby a bioprosthetic valve mounted on a stent is delivered and deployed on a stenotic valve

  • The black regions are those locations where the TAVI leaflets are in contact with its cuff and stent; these regions have no risk of thrombus formation

  • These predictions were compared between two common TAVI devices: Evolut and SAPIEN

Read more

Summary

Introduction

Transcatheter aortic valve implantation (TAVI) is a minimally invasive intervention whereby a bioprosthetic valve mounted on a stent is delivered and deployed on a stenotic valve. Subclinical leaflet thrombosis has been suggested as the underlying reason for hypoattenuated leaflet thickening (HALT) [5], leading to a reduced leaflet motion [2]. Reduced leaflet motion was resolved in up to 100% of the patients receiving anticoagulants compared to only 9% of those who did not [2]. The highest occurrence of HALT is reported for patients with a valve-invalve (ViV) implantation, whereby a TAVI is performed inside a degenerated surgical valve [3,4]. The exact prevalence of leaflet thrombosis remains unclear because it is clinically under-diagnosed [6]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call